TCM
QNCX icon

Tang Capital Management’s Quince Therapeutics QNCX Stock Holding History

Tang Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-922
Closed -$245K – 214
2025
Q1 		$245K Buy
+922
New +$282K 0.01% 194
2024
Q3 		– Sell
-7,500
Closed -$1.13M – 162
2024
Q2 		$1.13M Sell
7,500
-7,238
-49% -$1.31M 0.11% 91
2024
Q1 		$3.12M Sell
14,738
-1,362
-8% -$338K 0.33% 67
2023
Q4 		$3.38M Sell
16,100
-1,394
-8% -$279K 0.31% 74
2023
Q3 		$3.92M Sell
17,494
-572
-3% -$149K 0.55% 49
2023
Q2 		$5.44M Sell
18,066
-34
-0.2% -$10.6K 0.8% 35
2023
Q1 		$5.65M Buy
+18,100
New +$3.54M 0.84% 37

Other funds holding QNCX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Tang Capital Management's QNCX Position: Q2 2025 in Review

Tang Capital Management sold out of Quince Therapeutics (QNCX) in Q2 2025, closing a stake of 922 shares — an estimated $245K sold.

Tang Capital Management first reported a position in QNCX in Q1 2023 and held it in 7 quarters. The position peaked at $5.65M in Q1 2023. 37 funds tracked by Wall St. Rank hold QNCX as of Q2 2025.

  • Tang Capital Management reported no remaining Quince Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Tang Capital Management sold 922 Quince Therapeutics shares in Q2 2025, an estimated $245K.
  • Tang Capital Management first reported a position in Quince Therapeutics in Q1 2023 and held it in 7 quarters.
  • Tang Capital Management's Quince Therapeutics position peaked at $5.65M in Q1 2023.
  • 37 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.